Cargando…

Biomarkers in Anderson–Fabry Disease

Fabry disease is a rare lysosomal storage disorder caused by a deficiency of α-galactosidase A, resulting in multisystemic involvement. Lyso-Gb3 (globotriaosylsphingosine), the deacylated form of Gb3, is currently measured in plasma as a biomarker of classic Fabry disease. Intensive research of biom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simonetta, Irene, Tuttolomondo, Antonino, Daidone, Mario, Pinto, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662984/ https://www.ncbi.nlm.nih.gov/pubmed/33138098 http://dx.doi.org/10.3390/ijms21218080

Ejemplares similares

Pathogenesis and Molecular Mechanisms of Anderson–Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies
por: Tuttolomondo, Antonino, et al.
Publicado: (2021)

Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease
por: Tuttolomondo, Antonino, et al.
Publicado: (2017)

Case report: De novo mutation of a-galactosidase A in a female patient with end-stage renal disease: report of a case of late diagnosis of Anderson–Fabry disease
por: Simonetta, Irene, et al.
Publicado: (2023)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Anderson-Fabry disease in heart failure
por: Akhtar, M. M., et al.
Publicado: (2018)

Metabolic and Vascular Effect of the Mediterranean Diet
por: Tuttolomondo, Antonino, et al.
Publicado: (2019)

Anderson–Fabry Disease: From Endothelial Dysfunction to Emerging Therapies
por: Stamerra, Cosimo A., et al.
Publicado: (2021)

Biomarkers and Imaging Findings of Anderson–Fabry Disease—What We Know Now
por: Beirão, Idalina, et al.
Publicado: (2017)

Pathologic substrate of gastropathy in Anderson-Fabry disease
por: Di Toro, Alessandro, et al.
Publicado: (2020)

The distribution of hypertrophy in anderson fabry disease
por: Sado, Daniel M, et al.
Publicado: (2011)

Agalsidase alfa (Replagal(™)) in the treatment of Anderson-Fabry disease
por: Pastores, Gregory M
Publicado: (2007)

Advanced CMR Techniques in Anderson-Fabry Disease: State of the Art
por: Ponsiglione, Andrea, et al.
Publicado: (2023)

Role of cardiac imaging in Anderson-Fabry cardiomyopathy
por: Serra, Walter, et al.
Publicado: (2019)

Non-coding RNAs and other determinants of neuroinflammation and endothelial dysfunction: regulation of gene expression in the acute phase of ischemic stroke and possible therapeutic applications
por: Daidone, Mario, et al.
Publicado: (2021)

Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review
por: Caputo, Fabio, et al.
Publicado: (2021)

Cardiac Imaging in Anderson-Fabry Disease: Past, Present and Future
por: Esposito, Roberta, et al.
Publicado: (2021)

Clinical prodromes of neurodegeneration in Anderson-Fabry disease
por: Löhle, Matthias, et al.
Publicado: (2015)

Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease
por: Salamon, Irene, et al.
Publicado: (2021)

Time of Anderson-Fabry Disease Detection and Cardiovascular Presentation
por: Selthofer-Relatic, K.
Publicado: (2018)

Anderson–Fabry Disease: A New Piece of the Lysosomal Puzzle in Parkinson Disease?
por: Zedde, Marialuisa, et al.
Publicado: (2022)

Anderson-fabry disease: role of traditional and new cardiac MRI techniques
por: Caredda, Gloria, et al.
Publicado: (2021)

Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases
por: Maida, Carlo Domenico, et al.
Publicado: (2022)

CMR demonstration of multiple morphological phenotypes in Anderson-Fabry disease
por: Deva, Djeven P, et al.
Publicado: (2015)

Neuroinflammatory Mechanisms in Ischemic Stroke: Focus on Cardioembolic Stroke, Background, and Therapeutic Approaches
por: Maida, Carlo Domenico, et al.
Publicado: (2020)

Machine learning applications in stroke medicine: advancements, challenges, and future prospectives
por: Daidone, Mario, et al.
Publicado: (2023)

Cardiovascular magnetic resonance native T1 mapping in Anderson-Fabry disease: a systematic review and meta-analysis
por: Ponsiglione, Andrea, et al.
Publicado: (2022)

Anderson-Fabry’s Disease: A Rare but Treatable Case of Fever of Unknown Origin
por: Graziani, Francesca, et al.
Publicado: (2017)

Does left ventricular function predict cardiac outcome in Anderson–Fabry disease?
por: Spinelli, Letizia, et al.
Publicado: (2020)

Oxidative stress biomarkers in Fabry disease: is there a room for them?
por: Simoncini, C., et al.
Publicado: (2020)

Prognostic significance of right ventricular hypertrophy and systolic function in Anderson–Fabry disease
por: Graziani, Francesca, et al.
Publicado: (2020)

Angiokeratoma Corporis Diffusum: An Uncommon Case with Suspected Anderson Fabry Disease
por: Vadher, Priyanka, et al.
Publicado: (2020)

Molecular Biology of Atherosclerotic Ischemic Strokes
por: Tuttolomondo, Antonino, et al.
Publicado: (2020)

Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
por: Duro, Giovanni, et al.
Publicado: (2018)

Clinical Diversity in Patients with Anderson-fabry Disease with the R301Q Mutation
por: Yamamoto, Saori, et al.
Publicado: (2018)

Radiofrequency ablation of ventricular tachycardia in Anderson–Fabry disease: a case series
por: Mills, Mark T, et al.
Publicado: (2021)

Left atrial strain correlates with severity of cardiac involvement in Anderson-Fabry disease
por: Halfmann, Moritz C., et al.
Publicado: (2022)

Transcatheter Tricuspid Valve Replacement for Anderson Fabry Disease With Severe Tricuspid Regurgitation
por: Zhou, Guang-Wei, et al.
Publicado: (2022)

Association between Left Atrial Deformation and Brain Involvement in Patients with Anderson-Fabry Disease at Diagnosis
por: Esposito, Roberta, et al.
Publicado: (2020)

Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography
por: Dimitrow, Paweł Petkow, et al.
Publicado: (2005)

Evaluating enzyme replacement therapies for Anderson-Fabry disease: commentary on a recent report
por: Giugliani, Roberto, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b9rmfnekslb9q0na1ddv71odat